医学
低纤维蛋白原血症
内科学
天冬酰胺酶
纤维蛋白原
胃肠病学
单变量分析
发病机制
弥漫性血管内凝血
止血
回顾性队列研究
肿瘤科
免疫学
白血病
淋巴细胞白血病
多元分析
作者
Elisa Buzzatti,Fabio Forghieri,Giovangiacinto Paterno,Francesco Marchesi,Chiara Sarlo,Fabio Giglio,Nicola Fracchiolla,Mariarita Sciumè,Raffaele Palmieri,Fabiana Esposito,Luca Guarnera,Lisa Mercante,Maria Rosaria Pascale,Flavia Mallegni,Arianna Savi,Vittorio Forte,Luca Maurillo,Francesco Buccisano,Adriano Venditti,Maria Ilaria Del Principe
摘要
Hypofibrinogenemia (HF) in adult acute lymphoblastic leukemia (ALL) of B lineage is uncommon and mostly associated with asparaginase (ASP) delivery. Since we noticed a significant reduction in fibrinogen (FBG) plasma levels even before the first ASP dose, we aim to assess the levels of FBG during induction treatment and explore if the FBG fall correlated with therapies other than asparaginase and/or specific leukemia biological features. We retrospectively analyzed FBG levels in 115 patients with B-ALL. In 74 (64%) out of 115 patients FBG decline occurred during the steroid prephase. In univariate analysis, such a steroid-related HF was significantly associated with BCR-ABL1 rearrangement (p = 0.00158). None of those experiencing HF had significant modifications of liver function tests during induction treatment. Our retrospective study suggests that in B-ALL, steroid therapy can also induce HF and that such an event is preferentially observed in patients carrying BCR-ABL1 rearrangements. The pathogenesis of this phenomenon is still unclear. We attempt to explain it by applying the International Society of Thrombosis and Hemostasis-Disseminated Intravascular Coagulation score (ISTH-DIC score); nonetheless additional studies are needed to clarify further the mechanisms of HF in this subset of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI